Lilly: R&D agreement with Swiss firm for Alzheimer's disease
(CercleFinance.com) - Eli Lilly has said that it has signed a research and development (R&D) agreement with Swiss biotech firm AC Immune SA to explore small molecules for the potential treatment of Alzheimer's disease.
Under the terms of the deal, AC Immune will conduct the initial Phase 1 program, while Lilly will fund and conduct further clinical development.
Under the terms of the agreement, AC Immune will receive an upfront payment of 80 million Swiss francs (81 million dollars), along with 50 million dollars in exchange for a convertible note.
AC Immune will also be eligible to receive 60 million Swiss francs (61 million dollars) in potential near-term development milestones, as well as other milestone payments for up to 1.7 billion Swiss francs (1.7 billion dollars).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the deal, AC Immune will conduct the initial Phase 1 program, while Lilly will fund and conduct further clinical development.
Under the terms of the agreement, AC Immune will receive an upfront payment of 80 million Swiss francs (81 million dollars), along with 50 million dollars in exchange for a convertible note.
AC Immune will also be eligible to receive 60 million Swiss francs (61 million dollars) in potential near-term development milestones, as well as other milestone payments for up to 1.7 billion Swiss francs (1.7 billion dollars).
Copyright (c) 2018 CercleFinance.com. All rights reserved.